Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy

Combination PD-1 and CTLA-4 inhibitor therapy has dramatically improved the survival of patients with advanced melanoma but is also associated with significant immune-related toxicities. This study sought to identify circulating cytokine biomarkers of treatment response and immune-related toxicity....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2019-03, Vol.25 (5), p.1557-1563
Hauptverfasser:	Lim, Su Y, Lee, Jenny H, Gide, Tuba N, Menzies, Alexander M, Guminski, Alexander, Carlino, Matteo S, Breen, Edmond J, Yang, Jean Y H, Ghazanfar, Shila, Kefford, Richard F, Scolyer, Richard A, Long, Georgina V, Rizos, Helen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological - adverse effects Biomarkers, Tumor Combined Modality Therapy Cytokines - blood Drug-Related Side Effects and Adverse Reactions - etiology Female Follow-Up Studies Humans Immunomodulation - drug effects Male Melanoma - blood Melanoma - complications Melanoma - diagnosis Melanoma - drug therapy Middle Aged Neoplasm Staging Programmed Cell Death 1 Receptor - antagonists & inhibitors ROC Curve
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!